AveXis Revenue and Competitors
Estimated Revenue & Valuation
- AveXis's estimated annual revenue is currently $74.4M per year.
- AveXis received $460.0M in venture funding in January 2018.
- AveXis's estimated revenue per employee is $217,000
- AveXis's total funding is $75.1M.
Employee Data
- AveXis has 343 Employees.
- AveXis grew their employee count by -32% last year.
AveXis's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP Manufacturing & Supply Chain | Reveal Email/Phone |
2 | VP Field Execution & Strategy | Reveal Email/Phone |
3 | Associate Director Supplier Quality Management | Reveal Email/Phone |
4 | Director, Manufacturing Quality Assurance - Operations | Reveal Email/Phone |
5 | Associate Director Quality Assurance | Reveal Email/Phone |
6 | Associate Director, Supply Chain PMO | Reveal Email/Phone |
7 | Associate Director, Regional Medical Training | Reveal Email/Phone |
8 | Associate Director, Novartis Gene Therapies | Reveal Email/Phone |
9 | Executive Director Global Medical Information, Global Patient Safety, Grants & Managed Access | Reveal Email/Phone |
10 | Senior Director | Reveal Email/Phone |
AveXis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.8M | 18 | -14% | N/A | N/A |
#2 | $0.8M | 5 | 0% | N/A | N/A |
#3 | $2M | 13 | 0% | N/A | N/A |
#4 | $707.3M | 2852 | 14% | $1.1B | N/A |
#5 | $1.7M | 11 | 0% | N/A | N/A |
#6 | $32.6M | 210 | 6% | N/A | N/A |
#7 | $2.6M | 17 | 6% | N/A | N/A |
#8 | $1.1M | 7 | -30% | N/A | N/A |
#9 | $1.4M | 9 | -10% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is AveXis?
AveXis, Inc., a Novartis Company, is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality, and for the treatment of SMA Type 2. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1 and Type 2, we also plan to develop other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene. How to reach us: AveXis, Inc. 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: info@avexis.com Office Phone: 847.572.8280 Toll-free Phone: 844.4.AVEXIS (844.428.3947)
keywords:Biotechnology,Healthcare,Pharmaceuticals
$75.1M
Total Funding
343
Number of Employees
$74.4M
Revenue (est)
-32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
AveXis News
Novartis changed the name of AveXis to Novartis Gene Therapies in 2020. Novartis employs 2,270 people in Massachusetts and over 108,000 globally...
Novartis changed the name of AveXis to Novartis Gene Therapies in 2020. The company received incentives from the state of North Carolina for...
Helmed by R.A. Session II, who led corporate strategy and business development at AveXis before its $8.7 billion sale to Novartis,...
The global market for Spinal Muscular Atrophy Medicine has been analyzed in an in-depth market research report recently added to the rapidly ...
High-profile departures at Avexis raise more questions about Novartis's acquisition, but there were plenty of red flags before the deal was ...
Other Companies in Bannockburn
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35M | 539 | 8% | N/A |
#2 | $146.1M | 582 | 12% | N/A |
#3 | $52390M | 807 | -16% | N/A |
#4 | N/A | 2281 | 27% | N/A |
#5 | $3320M | 5760 | 8% | N/A |
AveXis Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-04-24 | $Undisclosed | Undisclosed | PBM Capital Group | Article |
| 2015-01-08 | $10.0M | Undisclosed | Deerfield Management | Article |
| 2015-09-10 | $65.0M | D | T. Rowe Price Associates | Article |
| 2017-06-21 | $230.0M | Undisclosed | Goldman Sachs & Co. LLC | Article |
| 2018-01-17 | $460.0M | Undisclosed | Goldman Sachs & Co. LLC | Article |